Denemek ALTIN - Özgür
AUSTRALIAN AGED CARE GETS BOOSTER DOSE
BioSpectrum Asia
|BioSpectrum Asia June 2021
In 2017, there were 3.8 million Australians aged 65 and over (comprising 15 per cent of the total population) —increasing from 319,000 (5 per cent) in 1927 and 1.3 million (9 per cent) in 1977. The number and proportion of older Australians is expected to continue to grow. By 2057, it is projected that there will be 8.8 million older people in Australia (22 per cent of the population); by 2097, 12.8 million people (25 per cent) will be aged 65 and over according to Australian Bureau of Statistics (ABS) 2017. Looking at the growing trend, the government of Australia has a separate ministry for Senior Australians and Aged Care Services and undertaken many steps to support them with respect, care and dignity.
The Australian Government has taken an important step to deliver its reforms to aged care by introducing the first legislation in response to the Royal Commission into Aged Care Quality and Safety. The Aged Care and Other Legislation Amendment (Royal Commission Response No. 1) Bill 2021 has been introduced into Parliament on May 27, 2021, and makes necessary changes to current aged care legislation, ahead of the new Aged Care Act planned for 2023.
This bill is the first step in the Government’s five-year, five-pillar, aged care reform plan addressing home care, residential aged care services and sustainability, residential care quality and safety, workforce and governance. The health, safety and wellbeing of senior Australians is of the utmost importance to the government, and is driving its plan for generational change of the aged care sector.
Minister for Health and Aged Care, Greg Hunt, said that the amendments will deliver immediate priority changes around restrictive practices, home care assurance reviews, and repeal the Aged Care Financing Authority. “Regulating the use of restrictive practices, like chemical and physical restraint, is a critical focus for the Australian Government to improve quality and safety of aged care”, Minister Hunt said.
“Addressing concerns raised by the Royal Commission and the independent review into restraint, our amendments will mean from July 1, we will have clearly defined restrictive practices, which align with the definitions used in the disability sector. We are strengthening legislation to ensure that restrictive practices are only used as a last resort, the impact on the care recipient is considered, and consent arrangements are clear,” said Hunt.
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia June 2021 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
BioSpectrum Asia'den DAHA FAZLA HİKAYE
BioSpectrum Asia
Seeing Opportunity in Ophthalmology
Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.
6 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Reshaping Asia's Healthcare with mRNA Innovation
The COVID-19 pandemic acted as both a challenge and a catalyst, serving as a testbed that fundamentally reshaped the biotechnology landscape across Asia and beyond. What emerged during this period was not just a breakthrough moment for mRNA, but the early foundation of a broader transformation that is still unfolding.
2 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Momentum in Motion: What Will Shape APAC's Life Sciences Landscape in 2026?
Asia-Pacific's life sciences sector is growing rapidly, driven by its scale, diversity and resilience. Accelerating demographic change and strong investment in innovation position the region to outpace global growth and shape the future of healthcare.
5 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
The Future of mRNA Is Being Built in APAC
Beyond scientific advancement, mRNA represents a strategic opportunity shaped by policy stability, public investment and regional collaboration. Across APAC, governments are increasingly recognising that supportive regulatory frameworks and long-term funding can serve as powerful competitive advantages, attracting global capital and talent. While political dynamics in the United States have slowed momentum, experts emphasise that the science underpinning mRNA technology remains sound. To fully realise its potential, the region will need greater coordination across borders, including regulatory harmonisation and joint development pathways, to build a resilient mRNA ecosystem capable of addressing shared health challenges and driving long-term innovation.
25 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
How Precision Medicine Is Reshaping Cancer Care
Despite major advances in cancer detection and treatment, high recurrence rates and progression to advanced disease continue to challenge outcomes across Asia-making precision medicine a critical catalyst for shifting cancer care from disease management toward treat-to-cure. By leveraging molecular insights, biomarker testing and collaborative healthcare ecosystems, precision medicine offers the potential to deliver more effective, personalised and sustainable cancer care for patients across the region.
2 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Repligen introduces next-generation chromatography resins
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India
Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh
\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.
1 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Cartherics names Dr lan Nisbet as CEO
Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Neurophet ropes in Josh Cohen as Head of Americas Business
South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.
1 min
BioSpectrum Asia Jan 2026
Translate
Change font size
